Pharmaceuticals Archives

ZYDUSLIFE – Q3 FY26 Earnings Call – 10-Feb-26

ZYDUSLIFE’s topline: 12–15% CAGR driven by US specialty, India chronic portfolio, and International Markets; Bottomline: 8–10% EPS growth contingent on margin stability and R&D efficiency; Margins: 23–25% EBITDA range, with upside from biosimilar scaling and downside from acquisition dilution.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Mirabegron settlement; CDMO revenue ramp-up in H2 FY27; biosimilar launches on schedule.
Outcome: US revenue grows 8–10% YoY, driven by specialty and generics volume. EBITDA margins stabilize at 23–25%. India and International Markets sustain 15–20% growth. Net debt reduces to ₹2,500Cr by FY28 as cash flows improve. GLP-1 captures 10–15% market share in India.

DIVISLAB – Q3 FY26 Earnings Call – 11-Feb-26

DIVISLAB’s growth relies on CS (57% mix), with generics resilient but pressured by pricing. Bottomline depends on CS commercialization (CY27) and cost pass-through, while margins face labor/raw material volatility, partly offset by backward integration and automation over 2–3 years.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) 2/3 CS projects commercialize in Q3–Q4 CY27; (2) Generic pricing stabilizes (China’s rebate removal lifts API prices by 3–5%). Outcome: Revenue 8–10% CAGR, EBITDA margins expand 50 bps (CS mix shift), and gross asset turnover improves to 1.4x by FY28. EPS grows 8–12% annually.

SUNPHARMA – Q3 FY26 Earnings Call – 31-Jan-26

Sun Pharma’s topline growth is milestone-dependent and exposed to US generics structural decline, while bottom-line resilience hinges on tax rate stabilization and R&D productivity; margins face near-term pressure from launch costs but could inflect in FY28 if innovative scales and OAI risks abate—model 31–33% EBITDA as the new range.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key variables: (1) OAI resolutions by late FY27, enabling 2–3 major ANDA launches; (2) Unloxcyt/LEQSELVI hit $200M run rate by FY28.
Outcome: Revenue grows 10–12% (ex-FX), with India/Semaglutide contributing 40% of incremental sales. EBITDA margins stabilize at 31–32%; EPS grows 6–8% on tax headwinds. Implication: In-line with consensus; 22–24x PE sustained.

CIPLA – Q3 FY26 Earnings Call – 23-Jan-26

Cipla’s topline resilience hinges on US pipeline execution (respiratory/peptides) and India chronic therapy growth, while margins face near-term pressure from R&D lumpiness and Lanreotide disruption; FY27 EBITDA recovery to 21%+ requires flawless launch sequencing and cost normalization.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Lanreotide resumes in H1 FY27; two respiratory launches in H1 FY27 (one sole generic).
Generic Victoza and one peptide launch in FY27; Yurpeak traction sustains (~₹150 crore/month).
Result: US revenue stabilizes at $130–150M/quarter; EBITDA margin recovers to 20–21%; FY27 guidance maintained at 21%.

DRREDDY – Q3 FY26 Earnings Call – 21-Jan-26

Dr.Reddy’s topline growth hinges on Semaglutide/Abatacept execution and EM resilience, while margins face structural pressure from Lenalidomide exit, FX, and biosimilar delays; base case implies 6–8% revenue growth with 24–26% EBITDA, but bear-case risks skew asymmetric.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Semaglutide launches in Canada (May 2026, $50/unit) and India (March 2026, $30/unit), contributing $150–200M revenue. Abatacept EU approval (July 2027) and US Rituximab re-inspection (H1CY27) proceed as guided. EM grows 20% YoY; India sustains 15%+ organic growth. EBITDA margins recover to 24–26% on cost controls. Implication: 6–8% revenue growth; 10–12% EPS growth.